Riluzole augmentation in treatment-resistant obsessive–compulsive disorder: an open-label trial
V Coric, S Taskiran, C Pittenger, S Wasylink… - Biological …, 2005 - Elsevier
BACKGROUND: Most patients with obsessive–compulsive disorder (OCD) show only partial
reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic
dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of
augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant
OCD. METHODS: Thirteen patients aged between 18 and 65 years with a primary diagnosis
of OCD that had proven resistant to standard treatment were treated with the addition of …
reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic
dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of
augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant
OCD. METHODS: Thirteen patients aged between 18 and 65 years with a primary diagnosis
of OCD that had proven resistant to standard treatment were treated with the addition of …